Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437316 | 0.95 | KDM4E (0.36) | CYP11B1CYP11B2PIK3CDALDH1A1 | |
| SCHEMBL17437537 | 0.82 | CYP3A4 (0.36) | CYP11B1CYP11B2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL16053822 | 0.78 | RPS6KA5 (0.32) | — | |
| SCHEMBL17437327 | 0.77 | ADORA3 (0.39) | — | |
| SCHEMBL17437317 | 0.76 | ALDH1A1 (0.33) | PIK3CDALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17437431 | 0.76 | KDM4E (0.31) | — | |
| SCHEMBL17437486 | 0.75 | SLC9A1 (0.33) | CYP11B1CYP11B2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL17437575 | 0.74 | RPS6KA5 (0.48) | CYP11B1CYP11B2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL17437394 | 0.74 | CYP1A2 (0.33) | CYP11B1CYP11B2CYP1A2CYP3A4 | |
| SCHEMBL17437312 | 0.72 | KDM4E (0.34) | CYP11B1CYP11B2PIK3CDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050963-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9512120-B2 | Microbicidally active imidazopyridine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-06 | — | — | US | disclosed |
| US-20160016949-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050963-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | IDO1, IDO2, FOXM1 | CYP11B1 1360/4885CYP11B2 1464/4885PIK3CD 721/4885 |
| US-20160016949-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | IDO1, IDO2, FOXM1 | CYP11B1 1360/4885CYP11B2 1464/4885PIK3CD 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.